



AUROBINDO PHARMA USA

ORGANIZATIONAL ANNOUNCEMENT

Aurobindo Pharma Acquires Certain Assets of Profectus BioSciences:

As a part of its strategy to broaden its presence in Healthcare space, Effective February 11, 2020, Aurobindo Pharma USA, Inc., finalized the asset acquisition transaction with Profectus BioSciences Inc. This new subsidiary is called ***Auro Vaccines LLC***.

Profectus BioSciences Inc. was a clinical-stage vaccine development company in the design and development of preventive and therapeutic vaccines for infectious diseases and oncolytic vaccines for cancer immunotherapy.

Through this asset purchase acquisition of Profectus BioSciences Inc., Aurobindo gets access to:

- Two Proprietary & Innovative technology platform - VesiculoVax™ (for Prophylactic use) & PBS Vax™ Platform (for therapeutic use) along with Global R&D center focused on emerging markets infectious diseases of public health and biodefense importance where there is significant opportunity for global health impact.
- Strong Scientific Team with world-class expertise in developing newer vaccines from basic discovery research into FDA-approved product.

Upon closing of the transaction, we have on-boarded 18 new employees under Auro Vaccines LLC. They are located at an existing building in Pearl River, New York.

We welcome the 18 employees and Auro Vaccines to our ever-growing Company!